No, the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines are not applicable to non-interventional studies (NIS) in the context of real-world evidence (RWE).
ICH GCP guidelines are designed to ensure the protection of human subjects and the quality and integrity of data generated in clinical trials of investigational medicinal products (IMPs). In contrast, NIS are observational studies that do not involve the administration of IMPs, and instead rely on the collection of data from routine clinical practice or other non-experimental settings.
However, there are other guidelines and frameworks that apply to non-interventional studies in the context of real-world evidence, such as the International Society for Pharmacoepidemiology’s (ISPE) “Guidelines for Good Pharmacoepidemiology Practices” (GPP).
It is important to note that while NIS may not be subject to the same regulatory requirements as clinical trials, they still need to adhere to the applicable local regulations, ethical and scientific standards, and to ensure the protection of patient privacy and confidentiality.
Share this story...
Real World Evidence (RWE) 101 – Patient Retention
RWE 101 - Patient Retention Long-term Real-World Evidence (RWE) studies face significant challenges when it comes to patient retention, for several reasons:[1] Time Commitment: Participants in RWE studies are [...]
Real World Evidence (RWE) 101 – Patient Recruitment
RWE 101 - Patient Recruitment Real-world evidence (RWE) is health care information derived from real-world data (RWD). It can be generated through various study designs or analyses, including pragmatic [...]
Real World Evidence (RWE) 101 – HARPER
RWE 101 - HARPER Regulatory agencies, health technology assessors, and payers are increasingly interested in studies that make use of real-world data to inform regulatory and other policy or [...]
Real World Evidence (RWE) 101 – STaRT-RWE
RWE 101 - STaRT-RWE START-RWE (Structured Template for Planning and Reporting on the Implementation of Real World Evidence Studies) was developed to address the need for improved transparency and [...]
Real World Evidence (RWE) 101 – Protocol Design and ISPE GPP
RWE 101 - Protocol Design and ISPE GPP The International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) are a set of best practices for the conduct [...]
Real World Evidence (RWE) 101 – Protocol Design and Scientific Best Practices
RWE 101 - Protocol Design and Scientific Best Practices Designing a robust Real-World Evidence (RWE) study is crucial for generating reliable and valid insights that are acceptable to regulators. [...]







